Onco-Innovations Stock Price, News & Analysis

Onco-Innovations (OTCQB:ONNVF) has appointed Dr. Michael Lock, Professor in Oncology and Medical Biophysics at the University of Western Ontario, to its Scientific and Clinical Advisory Board. Dr. Lock brings extensive experience in clinical trial design, translational oncology, and multidisciplinary cancer care.

Dr. Lock's distinguished career includes leadership roles as Chair of Radiation Oncology, Chief of Division of Radiation Oncology, and Medical Director of the London Regional Cancer Program. His international contributions include work with the IAEA, UN, and WHO. The appointment aims to support Onco's development of novel therapies, particularly its PNKP inhibitor program.

Additionally, the company's Board has approved a grant of 1,155,000 Restricted Share Units to directors, officers, and consultants.

Onco-Innovations (OTCQB:ONNVF) has initiated manufacturing activities with Dalton Pharma Services for its proprietary nanoparticle formulation, PEO-b-PBz-CL. This formulation is a crucial component of Onco's drug delivery platform designed to work with their PNKP inhibitor.

The manufacturing process will involve scale-up activities from 10 grams to 350 grams, focusing on optimization and establishing reproducible synthesis methods. Dalton will ensure the formulation meets quality specifications for purity, molecular weight, and residual solvent levels, while generating necessary analytical data for regulatory filings and future GMP manufacturing.

Onco-Innovations (OTCQB:ONNVF) announced that its subsidiary, Inka Health Corp., will chair and lead the fourth roundtable of Colorectal Cancer Canada's (CRC) Catalysts: Innovating for Tomorrow Series this fall. The virtual event will focus on data innovation and digital trust in oncology.

The roundtable will be chaired by Dr. Paul Arora, with expert speakers including Dr. Steve Jones from BC Cancer, Dr. Winson Cheung from the University of Calgary, and Inka Health Co-Founder Alind Gupta. The discussion will explore the integration of artificial intelligence, secure data sharing, and the application of emerging data sources in precision medicine.

Onco-Innovations (CBOE CA:ONCO) has appointed Dr. John Mackey, Professor Emeritus in Oncology at the University of Alberta, to its Scientific and Clinical Advisory Board. Dr. Mackey brings extensive experience in oncology, clinical trials, and drug development, having previously served as Director of the Clinical Trial Unit at Cross Cancer Institute and Executive Director of TRIO.

Dr. Mackey's credentials include co-founding Pacylex Pharmaceuticals, serving as CEO of illumiSonics, holding 12 patents, and co-authoring over 300 peer-reviewed publications. His expertise will support Onco's PNKP inhibitor program development, particularly in clinical strategy and trial methodology.

Onco-Innovations (OTCQB:ONNVF) has announced that over 90% of its $0.60 common share purchase warrants have been successfully exercised over an eight-month period. This high conversion rate has resulted in additional capital inflow for the company through non-dilutive financing.

CEO Thomas O'Shaughnessy highlighted that the significant warrant exercise rate demonstrates strong shareholder confidence in the company's strategic direction and validates their ability to generate internal capital.

Onco-Innovations (OTCQB:ONNVF) has successfully closed its previously announced non-brokered private placement, raising $400,000 through the issuance of 243,903 units at $1.64 per unit. Each unit comprises one common share and one warrant, with warrants exercisable at $2.05 per share until August 13, 2028.

The company will utilize the proceeds for general corporate and working capital purposes, including operational and R&D objectives. Additionally, 2,439 administrative shares were issued to a third party for services related to the placement. All securities are subject to a four-month hold period ending December 14, 2025.

Onco-Innovations (OTCQB:ONNVF) has signed a Start-Up Agreement with Avance Clinical to prepare for its first-in-human trial of their novel PNKP inhibitor therapy. The agreement focuses on developing crucial regulatory and clinical documentation required for human testing approvals.

Under the partnership, Avance will provide comprehensive support including: development of an Investigator's Brochure, creation of clinical trial protocols, conducting nonclinical gap analysis, and preparation for a pre-IND meeting with the FDA. The therapy targets advanced-stage cancers with PTEN1 or SHP-12 deficiency.

Onco-Innovations Limited (OTCQB:ONNVF) announced that its subsidiary Inka Health has been selected by OneMedNet (Nasdaq:ONMD) to lead an AI-driven oncology data analytics initiative. The project aims to develop external control arms (ECAs) using OneMedNet's regulatory-grade patient data to accelerate cancer therapy development.

The collaboration will utilize Inka Health's SynoGraph platform to validate an ECA for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer. This initiative targets the Real-World Evidence (RWE) market, projected to reach $4.6 billion by 2030. The project aims to demonstrate how real-world data can replicate traditional clinical trial results more efficiently, potentially reducing development costs and timelines.

The companies plan to submit their findings to ISPOR Europe 2025, positioning themselves at the forefront of AI-driven oncology research and drug development.

Onco-Innovations (OTCQB:ONNVF) has announced a non-brokered private placement to raise up to $400,000 through the issuance of 243,903 units at $1.64 per unit. Each unit includes one common share and one warrant, with warrants exercisable at $2.05 for 36 months.

The company will issue additional shares as a 1% administrative fee to a third party. Additionally, Onco-Innovations has approved the grant of 119,785 stock options and 960,000 restricted share units (RSUs) under its equity incentive plan. The proceeds will support general corporate purposes and R&D objectives.